文献速递水电解质与酸碱血液净化与透析

环硅酸锆钠降低透析前高钾血症的3b期随机对照研究

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
PubMed 文献 · J Am Soc Nephrol · 2019-06-14

DIALIZE研究为双盲、安慰剂对照、3b期多中心试验,纳入196例接受每周三次血液透析且透析前高钾的ESRD成人,随机接受安慰剂或环硅酸锆钠(非透析日每日一次5g,可滴定至最大15g)。主要终点为4周稳定剂量评估期内,至少四次透析中三次透析前血钾维持在4.0-5.0 mmol/L且无需紧急降钾治疗的患者比例。结果显示环硅酸锆钠组41.2%达到主要终点,安慰剂组仅1.0%(P<0.001),且耐受性良好。

要点

  • 环硅酸锆钠可有效维持透析前血钾在4.0-5.0 mmol/L。
  • 应答率显著高于安慰剂(41.2% vs 1.0%,P<0.001)。
  • 严重不良事件与安慰剂相当,低钾血症少见。

核心结论

  • 环硅酸锆钠对接受充分血液透析的ESRD患者透析前高钾血症有效且耐受性良好。

研究设计与样本

  • 双盲、安慰剂对照、3b期多中心研究,随机196例每周三次血液透析且透析前高钾的ESRD成人。
  • 环硅酸锆钠非透析日每日一次5g起始,每4周以5g递增滴定至最大15g,安慰剂对照。

主要发现

  • 环硅酸锆钠组41.2%达到主要终点,安慰剂组1.0%(P<0.001)。
  • 治疗期间需紧急降钾治疗者环硅酸锆钠组2.1%,安慰剂组5.1%。
  • 严重不良事件发生率环硅酸锆钠组7%、安慰剂组8%,两组透析间期体重增长相当,低钾血症事件少。

关键数值与推荐

  • 主要终点:4周稳定剂量评估期内,至少四次透析中三次透析前血钾4.0-5.0 mmol/L且无需紧急降钾治疗。
  • 环硅酸锆钠剂量滴定范围5g至最大15g,非透析日每日一次。

临床怎么用

  • 对于接受充分血液透析仍存在透析前高钾的ESRD患者,可考虑使用环硅酸锆钠以维持血钾正常。
  • 需在非透析日服药,并根据血钾水平滴定剂量,最大15g每日一次。

局限性

  • 研究期限较短,长期疗效与安全性未评估。
  • 样本量有限,亚组分析效力不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with ESRD have minimal renal potassium excretion and, despite hemodialysis, often have persistent predialysis hyperkalemia. The DIALIZE study (NCT03303521) evaluated sodium zirconium cyclosilicate (SZC) in the management of hyperkalemia in hemodialysis patients. METHODS: In the DIALIZE study, a double-blind, placebo-controlled, phase 3b multicenter study, we randomized adults with ESRD who were managed by three-times weekly hemodialysis and had predialysis hyperkalemia to receive placebo or SZC 5 g once daily on non-dialysis days, and titrated towards maintaining normokalemia over 4 weeks, in 5 g increments to a maximum of 15 g. The primary efficacy outcome was proportion of patients during the 4-week stable-dose evaluation period who maintained predialysis serum potassium of 4.0-5.0 mmol/L during at least three of four hemodialysis treatments after the long interdialytic interval and did not require urgent rescue therapy to reduce serum potassium. RESULTS: In total, 196 patients (mean [standard deviation (SD)] age =58.1 [13.7] years old) were randomized to sodium zirconium cyclosilicate or placebo. Of 97 patients receiving sodium zirconium cyclosilicate, 41.2% met the primary end point and were deemed treatment responders compared with 1.0% of 99 patients receiving placebo (P<0.001). Rescue therapy to reduce serum potassium during the treatment period was required by 2.1% of patients taking sodium zirconium cyclosilicate versus 5.1% taking placebo. Serious adverse events occurred in 7% and 8% of patients in sodium zirconium cyclosilicate and placebo groups, respectively. The two groups displayed comparable interdialytic weight gain. There were few episodes of hypokalemia. CONCLUSIONS: Sodium zirconium cyclosilicate is an effective and well-tolerated treatment for predialysis hyperkalemia in patients with ESRD undergoing adequate hemodialysis.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Fishbane S, Ford M, Fukagawa M, et al. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. J Am Soc Nephrol. 2019. PMID: 31201218. doi:10.1681/ASN.2019050450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。